Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for SHR-3201 injection and will conduct clinical trials in the near future. Indications for application: Alzheimer's disease.

SHR-3201 injection is a drug independently developed by the company to treat AD. It can remove biomarkers of disease in patients' brains and delay patients' cognitive decline. According to inquiries, no similar drugs have been approved for marketing at home or abroad. Up to now, the total R&D investment for SHR-3201 injection-related projects is approximately RMB 48.8 million (unaudited).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.